Analysis of pathophysiology of intestinal graft-versus-host disease after HLA-haploidentical stem cell transplantation

Analysis of pathophysiology of intestinal graft-versus-host disease after HLA-haploidentical stem cell transplantation - Intestinal GVHD after haplo-SCT

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000006648

Enrollment

Registered

2011-11-02

Start date

2011-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diseases that are treated with allogeneic stem cell transplantation, including acute myeloid leukemia, acute lymphoid leukemia, myelodysplastic syndrome, chronic myeloid leukemia, chronic lymphoid leukemia, myeloproliferative disorder, multiple myeloma, aplastic anemia, etc.

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who undergo HLA-haploidentical stem cell transplantation. Patients from whom we obtain written informed consent

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
To identify parameter of intestinal GVHD following HLA-haploidentical stem cell transplantation	—

Secondary

Measure	Time frame
1. Impact of TMA and viral infections on intestinal symptoms after haploidentical stem cell transplantation. 2. To identify the best therapy of intestinal GVHD. 3. The usefulness of PET/CT scan for the diagnosis of intestinal GVHD	—

Countries

Japan

Contacts

Public ContactKatsuji Kaida

Department of Internal Medicine, Hyogo College of Medicine Division of Hematology

kaidak@hyo-med.ac.jp0798-45-6886

Outcome results